| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.
HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...
Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $33 price t...
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.34) per share which missed the analyst consensus estimat...
Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform and lowers the price targ...